[Clinicopathological implications of gene alterations in breast cancer].
Recently, many alterations in DNA were demonstrated in human breast cancer in vivo, and their clinical and pathological implications were extensively examined. Among these gene alterations, amplification of the c-erbB-2 proto-oncogene and mutation of the p53 tumor-suppressor gene, which occur relatively frequently and are accompanied by alterations in the respective protein levels, demonstrated strong correlation to the histologic grade of atypia and were shown or suggested to be prognostic factors independent of tumor size or lymph node status. Although further analyses are necessary to clarify their prognostic significance in patients without lymph node metastasis, these are suggested to be useful in predicting patient prognosis more accurately and aiding determination of adjuvant systemic therapy.
Tsuda
H
H
Pathology Division, National Cancer Center Research Institute, Tokyo.
D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology*; D066246:ErbB Receptors / Q000235:genetics*; D005784:Gene Amplification; D016158:Genes, p53; D006801:Humans; D008207:Lymphatic Metastasis; D009154:Mutation; D009367:Neoplasm Staging; D011379:Prognosis; D000090063:Proto-Oncogene Mas; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D018719:Erb-b2 Receptor Tyrosine Kinases
D066246:ErbB Receptors; D000090063:Proto-Oncogene Mas; D011518:Proto-Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; C000715470:MAS1 protein, human